A New Method for Quantitative Analysis of Whole Blood Platelet Interaction With Extracellular Matrix Under Flow Conditions

Varon, David; Dardik, Rima; Шенкман, Борис; Kotev-Emeth, Shlomo; Farzame, Nahid; Tamarin, Ilia; Savion, Naphtali

doi:10.1016/s0049-3848(97)00014-5

Cited by 180 publications

(171 citation statements)

References 18 publications

Supporting

Mentioning

162

Contrasting

Unclassified

Order By: Relevance

“…The choice of the collagen dose used in the study was based, however, on a careful titration experiment; because collagen is prepared by extraction from biologic material, it is not clear whether lot-to-lot variability would require repeated titrations. A number of other functional assays are currently being studied for monitoring GP IIb/IIIa antagonist therapy, including thromboelastography; 33 assays based on the occlusion of apertures in membranes or tubing by platelet thrombi 34,35 ; and assays of shear-induced platelet deposition 36 and platelet-supported thrombin generation. 37,38 Our own attempt involves an assay based on the ability of activated platelets in anticoagulated whole blood to agglutinate fibrinogen-coated beads.…”

mentioning

confidence: 99%

Monitoring Platelet GP IIb/IIIa Antagonist Therapy

Coller

1998

Circulation

View full text Add to dashboard Cite

Platelet GP IIb/IIIa receptor antagonist therapy with abciximab (ReoPro), the Fab fragment of a mouse/ human chimeric version of the murine 7E3 antibody, is currently used to prevent ischemic complications of percutaneous coronary interventions in select cases, and the efficacy and safety of abciximab for other related indications are under study.1-4 A number of low-molecular-weight GP IIb/IIIa antagonists patterned on the arginine-glycine-aspartic acid (RGD) cell recognition sequence have also shown benefit in the prevention and treatment of ischemic thrombotic coronary artery disease and currently are in advanced stages of development and approval.

show abstract

mentioning

confidence: 99%

Monitoring Platelet GP IIb/IIIa Antagonist Therapy

Coller

1998

Circulation

View full text Add to dashboard Cite

show abstract

“…The bacterial cell suspensions were sheared (500 s Ϫ1 ) for 20 min at ambient temperature and removed from the microtiter wells. The wells were washed, and adherent microorganisms were stained with May Grunwald stain (Sigma Chemical Co.) as described previously (31). Bacterial cell adhesion was evaluated microscopically (ϫ40), using a computer-driven software program that quantifies the percent surface coverage (27,31).…”

Section: Methodsmentioning

confidence: 99%

“…The wells were washed, and adherent microorganisms were stained with May Grunwald stain (Sigma Chemical Co.) as described previously (31). Bacterial cell adhesion was evaluated microscopically (ϫ40), using a computer-driven software program that quantifies the percent surface coverage (27,31). The same assay was used to evaluate the effect of gC1qR blockade in vitro by the addition of either MAb 60.11 or MAb 74.5.2 (10 to 100 g/ml) or purified S. aureus protein A (100 g/ml) (Sigma Chemical Co.).…”

Section: Methodsmentioning

confidence: 99%

gC1qR/p33 Blockade ReducesStaphylococcus aureusColonization of Target Tissues in an Animal Model of Infective Endocarditis

et al. 2006

View full text Add to dashboard Cite

“…IMPACT (Image Analysis Monitoring Platelet Adhesion Cone and Plate Technology) Cone and Plate(let) Analyzer (CPA) (DiaMed, Cressier, Switzerland) is a new POC completely automated system that evaluates platelet function simulating in vitro primary haemostasis [4,27,28,128] . Citrated WB is exposed to shear stress by the spinning of a cone in a standardized polystyrene plate.…”

Section: Impact Cone and Plate(let) Analyzermentioning

confidence: 99%

“…Therefore, this instrument methodology should be a reliable device for the diagnosis of platelet defects. Moreover, the addition of the agonists AA and ADP in the system allows to monitor dual antiplatelet therapy [128][129][130] . This system still needs an experienced use and additional studies must be conducted for assessing its possible role for monitoring inherited or acquired platelet dysfunctions.…”

Section: Impact Cone and Plate(let) Analyzermentioning

confidence: 99%

Assessment of platelet function: Laboratory and point-of-care methods

Paniccia¹

2014

WJTM

View full text Add to dashboard Cite

In the event of blood vessel damage, human platelets are promptly recruited on the site of injury and, after their adhesion, activation and aggregation, prevent blood loss with the formation of a clot. The consequence of abnormal regulation can be either hemorrhage or the development of thrombosis. Qualitative and/or quantitative defects in platelets promote bleeding, whereas the residual reactivity of platelets, despite antiplatelet therapies, play an important role in promoting arterial thrombotic complications. Platelet function is traditionally assessed to investigate the origin of a bleeding syndrome, to predict the risk of bleeding prior surgery or during pregnancy or to monitor the efficacy of antiplatelet therapy in thrombotic syndromes that, now, can be considered a new discipline. "Old" platelet function laboratory tests such as the evaluation of bleeding time and the platelet aggregation analysis in platelet-rich plasma are traditionally utilized to aid in the diagnosis and management of patients with platelet and hemostatic disorders and used as diagnostic tools both in bleeding and thrombotic diathesis in specialized laboratories. Now, new and renewed automated systems have been introduced to provide a simple, rapid assessment of platelet function including point of care methods. These new methodologies are also suitable for being used in non-specialized laboratories and in critical area for assessing platelet function in whole blood without the requirement of sample processing. Some of these methods are also beginning to be incorporated into routine clinical use and can be utilized as not only as first panel for the diagnosis of platelet dysfunction, but also for monitoring anti-platelet therapy and to potentially assess risk of both bleeding and/or thrombosis.© 2014 Baishideng Publishing Group Inc. All rights reserved.Key words: Platelets; Method; Test; Point of care testing; Laboratory assessment; Bleeding; Thrombosis; Platelet function Core tip: This review discussed the scenario of available platelet function laboratory and point-of-care methods suitable in different clinical setting. As this matter has become of crucial importance in the bleeding management and for monitoring antiplatelet therapies, improved ability to assess platelet function in a timely and efficient manner is essential. Traditional platelet function methods, requiring a fair degree of expertise, have been limited to specialized laboratory. Many efforts have been carried out for improving platelet function assays for centralized laboratory, such as different point-of-care testing methodologies have been developed. Moreover, different guidelines and recommendations for their method standardization are growing.

show abstract

A New Method for Quantitative Analysis of Whole Blood Platelet Interaction With Extracellular Matrix Under Flow Conditions

Cited by 180 publications

References 18 publications

Monitoring Platelet GP IIb/IIIa Antagonist Therapy

Monitoring Platelet GP IIb/IIIa Antagonist Therapy

gC1qR/p33 Blockade ReducesStaphylococcus aureusColonization of Target Tissues in an Animal Model of Infective Endocarditis

Assessment of platelet function: Laboratory and point-of-care methods

Contact Info

Product

Resources

About